New drug aims to supercharge chemo against aggressive lung cancer
NCT ID NCT04560972
Summary
This early-stage study is testing a new drug, LB-100, to see if it makes standard chemotherapy and immunotherapy work better against extensive-stage small cell lung cancer. The main goals are to find the safest and most effective dose of LB-100 and to check for side effects when it's combined with other cancer drugs. The hope is that blocking a specific protein with LB-100 will make cancer cells more vulnerable to the other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.